Kyverna's Miv-cel Shows Durable Efficacy in Rare Neurologic…

Event summary

Kyverna reported one-year data showing durable clinical responses and favorable safety profile for miv-cel in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).
95% of SPS patients sustained clinically meaningful improvements at 12 months, with no high-grade CRS or ICANS observed.
All gMG patients achieved clinically meaningful improvement in key endpoints, with 57% maintaining minimal symptom expression at last follow-up.
Rolling BLA submission for miv-cel in SPS on track for completion in Q4 2026.
Phase 3 enrollment for gMG expected to complete in mid-2027.

The big picture

Kyverna's positive one-year data for miv-cel reinforces its potential as a transformative therapy for rare neurologic autoimmune diseases, positioning the company at the forefront of CAR T-cell therapy innovation. The favorable safety profile and durable efficacy results could set a new benchmark for autoimmune CAR T treatments, addressing significant unmet needs in SPS and gMG. The strategic focus on regulatory approval and clinical trial progress will be critical in determining the long-term success of miv-cel in this emerging therapeutic landscape.

What we're watching

Regulatory Approval: Whether the rolling BLA submission will meet FDA expectations and secure approval for miv-cel in SPS by the end of 2026.
Clinical Trial Progress: The pace at which Phase 3 enrollment for gMG will be completed and whether the trial will replicate the positive results seen in Phase 2.
Market Potential: How Kyverna will position miv-cel as a potential first-in-class therapy for neurologic autoimmune diseases and capture market share in SPS and gMG.